Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study
出版年份 2013 全文链接
标题
Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study
作者
关键词
-
出版物
CANCER INVESTIGATION
Volume 31, Issue 5, Pages 336-345
出版商
Informa UK Limited
发表日期
2013-05-04
DOI
10.3109/07357907.2013.793699
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Polymorphisms in the cytotoxic T-lymphocyte antigen 4 gene and cancer risk
- (2011) Yonggang Zhang et al. CANCER
- Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors
- (2011) Ahmad Tarhini et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- (2011) Rui-Ru Ji et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use
- (2011) Zahra Hanaizi et al. EUROPEAN JOURNAL OF CANCER
- T-Cell Activation and Maturation at Tumor Site Associated With Objective Response to Ipilimumab in Metastatic Melanoma
- (2011) Michele Del Vecchio et al. JOURNAL OF CLINICAL ONCOLOGY
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- Melanoma drug wins US approval
- (2011) Heidi Ledford NATURE
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- (2010) Geoffrey Y. Ku et al. CANCER
- Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers
- (2010) David B Page et al. Immunotherapy
- Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
- (2010) Helen Gogas et al. Journal of Translational Medicine
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy
- (2010) Margaret K. Callahan et al. SEMINARS IN ONCOLOGY
- Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies
- (2009) Santiago Rodriguez et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- CTLA-4 +49A>G polymorphism of recipients of HLA-matched sibling allogeneic stem cell transplantation is associated with survival and relapse incidence
- (2009) Patrizia Piccioli et al. ANNALS OF HEMATOLOGY
- Ipilimumab: controversies in its development, utility and autoimmune adverse events
- (2009) Jeffrey Weber CANCER IMMUNOLOGY IMMUNOTHERAPY
- Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?
- (2009) Marna G. Bouwhuis et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Genetic Polymorphisms in Cytotoxic T-Lymphocyte Antigen 4 and Cancer: The Dialectical Nature of Subtle Human Immune Dysregulation
- (2009) T. Sun et al. CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies
- (2009) Annalisa Brozzetti et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade
- (2009) Willemijn B. Breunis et al. JOURNAL OF IMMUNOTHERAPY
- Functional Genetic Variations in Cytotoxic T-Lymphocyte Antigen 4 and Susceptibility to Multiple Types of Cancer
- (2008) T. Sun et al. CANCER RESEARCH
- Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
- (2008) A. Ribas et al. CLINICAL CANCER RESEARCH
- Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers
- (2008) Ahmad A Tarhini et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Genomic regulation of CTLA4 and Multiple Sclerosis
- (2008) Ricardo Palacios et al. JOURNAL OF NEUROIMMUNOLOGY
- CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- (2008) C. I. Liakou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started